Treatment duration and long-term outcomes with daratumumab in transplant-ineligible newly diagnosed multiple myeloma from the phase 3 MAIA study

被引：0

作者：

Moreau, Philippe ^{[1
]}

Facon, Thierry ^{[2
]}

Usmani, Saad ^{[3
]}

Kumar, Shaji ^{[4
]}

Plesner, Torben ^{[5
,6
]}

Goldschmidt, Hartmut ^{[7
,8
]}

Orlowski, Robert ^{[9
]}

Perrot, Aurore ^{[10
]}

Chari, Ajai ^{[11
]}

Cook, Gordon ^{[12
]}

Pei, Huiling ^{[13
]}

Van Rampelbergh, Rian ^{[14
]}

Bartlett, J. Blake ^{[15
]}

Uhlar, Clarissa ^{[16
]}

Carson, Robin ^{[16
]}

Bahlis, Nizar ^{[17
]}

机构：

[1] Univ Hosp Hotel Dieu, Dept Hematol, Nantes, France

[2] Univ Lille, CHU Lille, Serv Malad Sang, Lille, France

[3] Mem Sloan Kettering Canc Ctr, New York, NY USA

[4] Mayo Clin Rochester, Dept Hematol, Rochester, MN USA

[5] Vejle Hosp, Vejle, Denmark

[6] Univ Southern Denmark, Vejle, Denmark

[7] Univ Hosp Heidelberg, Internal Med 5, Heidelberg, Germany

[8] Natl Ctr Tumor Dis NCT, Heidelberg, Germany

[9] Univ Texas MD Anderson Canc Ctr, Dept Lymphoma Myeloma, Houston, TX USA

[10] Inst Univ Canc Toulouse Oncopole, Toulouse, France

[11] Icahn Sch Med Mt Sinai, New York, NY USA

[12] Leeds Inst Clin Trials Res, Leeds Canc Res UK CTU, Leeds, W Yorkshire, England

[13] Janssen Res & Dev LLC, Titusville, NJ USA

[14] Janssen Res & Dev, Beerse, Belgium

[15] Janssen Res & Dev LLC, Raritan, NJ USA

[16] Janssen Res & Dev LLC, Spring House, PA USA

[17] Univ Calgary, Calgary, AB, Canada

来源：

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2022年 / 22卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

OAB-039

引用

页码：S23 / S24

页数：2

共 50 条

[41] Unravelling transplant-ineligible newly diagnosed multiple myeloma treatment in real-world practice in Spain: CARINAE study
Casanova Espinosa, Maria
Hernandez Garcia, Miguel Teodoro
Soler Campos, Juan Alfons
Herraez Rodriguez, Susana
Moreno Belmonte, Maria Jose
Gonzalez-Pardo, Miriam
Gironella Mesa, Mercedes
de Arriba de la Fuente, Felipe
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S93 - S94
[42] Phase 3 FIRST Trial in Transplant-Ineligible Newly Diagnosed Multiple Myeloma: Subgroup Analysis of Patients From Canada and the United States
Belch, Andrew
Bahlis, Nizar J.
White, Darrell
Cheung, Matthew
Chen, Christine
Shustik, Chaim
Song, Kevin
Tosikyan, Axel
Dispenzieri, Angela
Anderson, Kenneth C.
Kotey, Stanley
Brown, Diane
Robinson, Suzanne
Srinivasan, Shankar
Facon, Thierry
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2019, 19 (10): : E225 - E225
[43] Phase 1/2 study of weekly carfilzomib, cyclophosphamide, dexamethasone in newly diagnosed transplant-ineligible myeloma
Bringhen, S.
D'Agostino, M.
De Paoli, L.
Montefusco, V.
Liberati, A. M.
Galieni, P.
Grammatico, S.
Muccio, V. E.
Esma, F.
De Angelis, C.
Musto, P.
Ballanti, S.
Offidani, M.
Petrucci, M. T.
Gaidano, G.
Corradini, P.
Palumbo, A.
Sonneveld, P.
Boccadoro, M.
LEUKEMIA, 2018, 32 (04) : 979 - 985
[44] Unravelling Transplant-Ineligible Newly Diagnosed Multiple Myeloma Treatment in Real-World Practice in Spain: The CARINAE Study
de la Fuente, Felipe de Arriba
Mesa, Mercedes Gironella
Garcia, Miguel Teodoro Hernandez
Campos, Juan Alonso Soler
Rodriguez, Susana Herraez
Belmonte, Maria Jose Moreno
Lopez, Teresa Regueiro
Gonzalez-Pardo, Miriam
Espinosa, Maria Casanova
PHARMACEUTICALS, 2024, 17 (10)
[45] Impact of Treatment Sequencing on Overall Survival in Patients with Transplant-Ineligible Newly Diagnosed Myeloma
Fonseca, Rafael
Facon, Thierry
Hashim, Mahmoud
Nair, Sandhya
He, Jianming
Ammann, Eric
Lam, Annette
Wildgust, Mark
Kumar, Shaji
ONCOLOGIST, 2023, 28 (05): : E263 - E269
[46] Practice Patterns in Front-line Treatment of Transplant-Eligible and Transplant-Ineligible Newly Diagnosed Multiple Myeloma
Poy, Theprungsirikul
Liu Yuxin
Natalia, Neparidze
AMERICAN JOURNAL OF HEMATOLOGY, 2023, 98 : S28 - S28
[47] Phase 1/2 study of weekly carfilzomib, cyclophosphamide, dexamethasone in newly diagnosed transplant-ineligible myeloma
S Bringhen
M D'Agostino
L De Paoli
V Montefusco
A M Liberati
P Galieni
S Grammatico
V E Muccio
F Esma
C De Angelis
P Musto
S Ballanti
M Offidani
M T Petrucci
G Gaidano
P Corradini
A Palumbo
P Sonneveld
M Boccadoro
Leukemia, 2018, 32 : 979 - 985
[48] Daratumumab Improves Depth of Response and Progression-free Survival in Transplant-ineligible, High-risk, Newly Diagnosed Multiple Myeloma
Jakubowiak, Andrzej J.
Kumar, Shaji
Medhekar, Rohan
Pei, Huiling
Lefebvre, Patrick
Kaila, Shuchita
He, Jianming
Lafeuille, Marie-Helene
Cortoos, Annelore
Londhe, Anil
Mavros, Panagiotis
Lin, Thomas S.
Usmani, Saad Z.
ONCOLOGIST, 2022, 27 (07): : E589 - E596
[49] Daratumumab, bortezomib, melphalan, and prednisone versus bortezomib, melphalan, and prednisone alone in transplant-ineligible Asian patients with newly diagnosed multiple myeloma: final analysis of the phase 3 OCTANS Study
Fu, Weijun
Bang, Soo-Mee
Huang, Honghui
Kim, Kihyun
Li, Wei
An, Gang
Lee, Je-Jung
Cai, Zhen
Jin, Jie
Wang, Yafei
Chim, Chor Sang
Carson, Robin
Liu, Rui
Zhao, Man
Chen, Xi
Cui, Canchan
Hou, Jian
Wang, Jianxiang
ANNALS OF HEMATOLOGY, 2025, 104 (01) : 515 - 525
[50] Phase 3 Randomized Study of Daratumumab Plus Lenalidomide and Dexamethasone (D-Rd) Versus Lenalidomide and Dexamethasone (Rd) in Patients with Newly Diagnosed Multiple Myeloma (NDMM) Ineligible for Transplant (MAIA)
Facon, Thierry
Kumar, Shaji K.
Plesner, Torben
Orlowski, Robert Z.
Moreau, Philippe
Bahlis, Nizar
Basu, Supratik
Nahi, Hareth
Hulin, Cyrille
Quach, Hang
Goldschmidt, Hartmut
O'Dwyer, Michael
Perrot, Aurore
Venner, Christopher P.
Weisel, Katja
Mace, Joseph R.
Ahmadi, Tahamtan
Chiu, Christopher
Wang, Jianping
Van Rampelbergh, Rian
Uhlar, Clarissa M.
Kobos, Rachel
Qi, Ming
Usmani, Saad Z.
BLOOD, 2018, 132

← 1 2 3 4 5 →